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Abstract 
In 2006, scientists participating to the Human Liver Proteome Project (HLPP) launched 
by the Human Proteome Organisation (HUPO) convened on two occasions to present and 
discuss their progress.  A workshop was held over two days in May in Bilbao, Spain, and a brief 
3-hour meeting was held in October in conjunction with the 5th HUPO World Congress in Long 
Beach, California.  Highlights included progress on the construction of the human normal liver 
proteome expression profile and of subcellular proteomes, establishment of a liver ORFeome 
bank and of a liver antibody bank, identifications of protein-protein interaction maps in the liver, 
application of a robust strategy for quantitative proteomics and the characterization of fatty liver 
diseases using mouse models. 
The scientific objectives of HLPP are to characterize the proteome of the healthy human liver 
(expression profiling, cellular localization, post-translational modifications, protein-protein 
interactions) and to develop tools for its study (sample banking, ORFeome, antibodies).  The 
information and tools that are generated by this international effort will be available to the 
scientific community with the hope that they will help understand, diagnose and treat liver 
diseases more effectively. 
 At the 2005 HLPP workshop held at the Airlie Center, USA, initial targets for HLPP 
were identified, as follows: 1- identification of 5,000 individual proteins in the normal human 
liver; 2- availability of antibodies against these 5,000 proteins; 3- determination of the presence 
of these 5,000 proteins in plasma.  The aim of these targets is to generate sufficient knowledge of 
the normal liver and resources to allow the study of liver diseases and biomarker discovery.  As 
learned during the 2006 workshops, major progress has been made toward these goals.  The 2006 
annual HLPP Workshop was held May 4-5 in Bilbao, Spain.  The workshop was hosted by Dr. 
José Mato (CIC bioGUNE) and sponsored by the Banco Bilbao Vizcaya Argentaria (BBVA) 
Foundation.  The meeting took place in a restored historic building in downtown Bilbao, the 
19th-century home of BBVA: an elegant setting for a valuable exchange of ideas.  The Fall 2006 
HLPP Workshop was held October 29 at the Long Beach Convention Center, California, 
immediately prior to the HUPO 5th Annual World Congress.  The workshop was hosted by Dr. 
Laura Beretta, Fred Hutchinson Cancer Research Center, current chair of the HLPP.  This report 
summarizes the presentations and subsequent discussion. 
Drs. Fuchu He, Xiaohong Qian and Wantao Ying from the Beijing Proteome Research 
Center are leading the effort on the HLPP subproject on expression profiling in China and 
presented in both workshops important progress in the construction of the human normal liver 
proteome expression profile.  The achievements presented during the workshops included: 1/ 
standardization of tissue acquisition, sample processing, protein extraction, protein/peptide 
separation and identification and data submission and management; 2/ the semi-integration of 
data from multiple platforms, the semi-quantitative analysis of shotgun data, the comparison 
between SDS-PAGE, 2-DE, shotgun and LC-shotgun, preliminary annotation of key 
physiological and pathological pathways in the liver and GO annotation.  For the next phase, 
these groups plan on focusing on the profiling of subcellular organelles including quantitative 
analysis using high accuracy mass spectrometry; isolation of hepatocytes and other liver cell 
types and their profiling analysis; characterization of post-translational modifications of liver 
proteins; standardization for data quality control at both the peptide and the protein levels; and 
intra- and inter-organelle quantification of proteins.  To date, the expression profiling of the 
human fetal liver has been finalized with 2,495 unique proteins identified and reported [1].  The 
data are also publicly available in the PRIDE database at the European Bioinformatics Institute 
(www.ebi.ac.uk/pride/startBrowse.do) by selecting the heading: “HUPO HLPP: Beijing 
Proteome Research Center” (accession numbers 1779 through 1853).  The expression profiling 
of the first adult liver reference sample (referred to as the French liver sample) is also finalized 
with 4,998 unique proteins identified.  The expression profiling of the second adult liver 
reference sample (referred to as the Chinese liver sample) is currently under analysis with 6,788 
proteins identified to date. 
Dr. Laura Beretta, Fred Hutchinson Cancer Research Center in Seattle, presented the 
analysis performed by her group on the profiling of the adult liver reference sample.  The work 
was described in three sections: methods used for protein extraction, separation and 
identification; comparison between the transcriptomic and proteomic profiles of the reference 
sample and comparisons with the human fetal liver and the human plasma proteome.  Intact 
proteins extracted from the reference sample were extensively separated using a three-
dimensional approach (a combination of 2D HPLC and SDS-PAGE).  Following in-gel 
digestion, the resulting peptides were analyzed by LC-MS/MS.  The generated data were 
submitted to CPAS (Computational Proteomics Analysis System) developed at the Fred 
Hutchinson Cancer Research Center, using the X!Tandem search engine and ProteinProphet.  
Using a cut-off of 0.9 ProteinProphet score, 8149 individual proteins and 472 protein groups 
were identified by at least 3 peptides.  A relative protein abundance score was calculated for each 
identified protein.  Annotation of the identified proteins with properties such as MW, Gene 
Ontology classification and post-translational modifications is underway.  In parallel, the 
transcriptomic profile of the same sample was established using Affymetrix chips containing 
54,675 probe sets.  This analysis identified 10,982 genes expressed in the reference liver sample.  
Comparative analysis of the transcriptomic and the proteomic data sets was presented.  The 
results indicated that protein products for over 50% of the genes expressed were identified using 
this proteomic approach, including protein products of low-abundance genes.  Comparison with 
the human fetal liver proteome recently published [1] identified 945 (out of 1807) proteins 
commonly expressed in both fetal and adult livers.  Comparison with the HPPP human plasma 
proteome [2] identified 792 (out of 3017) proteins detected in both plasma and liver tissue.  
Future directions for Dr. Beretta’s group are to refine the criteria for selection of candidate 
disease markers, to prioritize proteins for production of antibodies, to further compare liver and 
plasma proteomes, to evaluate and validate methods for label-free protein quantification. 
Drs. John Bergeron and Alexander Bell from McGill University, Montreal presented their 
quantitative proteomic study of detoxification in the hepatic endoplasmic reticulum (ER).  ER 
organelles in the liver play an essential role not only in protein synthesis and folding but also in 
liver detoxification.  The proteomes of highly enriched organellar ER rough and smooth 
membranes and Golgi fractions from rat liver were characterized.  Organellar proteins were 
resolved by 1D-SDS PAGE, the gels were sliced and the proteins were in-gel digested with 
trypsin.  Peptides were extracted and subjected to LC-QTOF MS analysis.  Identified proteins 
were annotated into 23 functional categories and the detoxification category was further curated 
into 13 sub-functions.  The Cytochrome P450, Glucuronosyltransferase and Carboxylesterase 
families of proteins, with 34, 11 and 9 isoforms identified, respectively, represented about 67% 
of the total ER protein as determined by redundant peptide counting although these highly 
sequence related families represented only 54 of the 122 detoxification proteins.  Peptide 
heatmaps, revealing frequency, identification and location of peptides (assigned at >95% 
confidence) in these families were emphasized.  KDEL- and KKxx/KxKxx-related trafficking 
motifs were identified in the Carboxylesterase and Glucuronosyltransferase proteins whereas 
several Cytochrome P450s revealed an exposed DxD motif (as deduced from their x-ray 
crystallography) that may be involved in trafficking.  Peptide sequencing information was 
presented that distinguishes Cytochrome P450 allelic isoforms and database DNA sequencing 
errors were identified.  Proteomics readily distinguished multiple members of the Cytochrome 
P450, Glucuronosyltransferase and Carboxylesterase families of proteins, distinguished allelic 
isoforms differing by a single amino acid and corrected DNA-related sequencing errors in the 
protein database. 
 Dr. Ying Jiang from the Beijing Proteome Research Center has been developing sample 
preparation strategies for the analysis of subcellular proteomes using livers from C57BL/6J strain 
mice.  This study has been recently published [3].  Dr. Siqi Liu from the Beijing Genomics 
Institute presented data mining analysis on cellular organelles (specifically on mitochondria with 
over 600 proteins involved in all metabolic pathways in this organelle) and validation by other 
proteomic approaches. 
Dr. Pengyuan Yang from the Institute of Biomedical Sciences and the Fudan University 
Proteomics Research Center in Shanghai, reported the identification of 15,765 genes expressed 
in the human liver, of which 13,211 correspond to protein-coding genes.  Approximately 5,500 
open reading frames (ORFs) of genes expressed in the human liver have been cloned.  Of these 
5,500 ORFs, approximately 4,000 have been constructed into vectors for use in yeast two-hybrid 
assays.  The majority of these ORF clones are in the range of 500-1500 base pairs in length.  A 
web interface has been created in order to access the current ORF bank data set 
(http://202.127.18.238/hlpp/).   
 Dr. Xiaoming Yang from the Beijing Proteome Research Center presented the 
undergoing effort to establish a liver protein-protein interaction (PPI) map.  To date, 1249 baits 
have been used for PPI studies.  Approximately 30 baits per day can be processed in yeast two-
hybrid assays.  Antibody chips containing over 1000 probes are also used for this subproject.  
The resulting data are further validated by co-immunoprecipitation or by affinity purification.  
The largest network identified to date includes 1035 PPIs between 810 proteins.  A primary map 
was presented and the functions of specific interactions, such as those involved in the Keap1-
Nrf2-ARE signaling pathway, were examined in detail. 
Dr. Qihong Sun from the Beijing Proteome Research Center is working towards the 
development of a liver antibody bank.  Dr. Sun and colleagues have reported a strategy to 
establish the antibody bank of murine monoclonal antibodies for human liver proteins using 
fractionated native liver proteins as immunogens.  Synthesized peptides from liver-specific 
proteins and purified recombinant protein antigens have been used as well.  To date, 1907 
hybridoma cell lines have been established.  Of these cell lines, 1400 have been characterized 
and produced monoclonal antibodies for approximately 150 different proteins.  Rabbit polyclonal 
antibodies have been produced for 56 different proteins.  Approximately 44% of the hybridoma 
cell lines have been assigned to immune response functions and approximately 41% of the 
monoclonal antibodies have been assigned to metabolic functions.  The produced antibodies are 
currently used for depletion of highly abundant proteins expressed in liver tissues or plasma, for 
immunohistochemistry and for isolation of protein complexes. 
Dr. José Mato from CIC bioGUNE in Bilbao, Spain, introduced different approaches to 
study the early stages of steatosis and steatohepatitis using genomics, metabolomics and 
proteomics.  Dr. Mato introduced mouse models of non-alcoholic fatty liver disease (NAFLD) 
leading to hepatocellular carcinoma.  These models target the metabolism of methionine and 
include MAT1A knockout mice.  The MAT1A KO mice spontaneously develop steatohepatitis 
and later hepatocellular carcinoma.  Another key player in the metabolism of methionine is 
GNMT.  Interestingly, a GNMT polymorphism has been reported to be associated with HCC in 
humans.  GNMT KO mice have been generated.  These mice spontaneously develop 
steatohepatitis and fibrosis.  Liver disease progression in older mice is under investigation.  The 
integrative gene expression profiling of liver biopsies of NASH patients with liver samples of 
MAT1A KO mice identified genes and gene pathways that are associated with NASH.  Based on 
this information, Dr. Mato’s group generated a novel mouse model and, remarkably, the mice 
spontaneously develop steatohepatitis.  Proteomic analysis of liver tissues from patients with 
steatosis or with NASH was performed using 2D gel electrophoresis (DIGE) to identify proteins 
differentially-expressed in NASH and in steatosis.  Proteomics and metabolomics studies of sera 
from controls, patients with steatosis and patients with NASH were also performed.  The 
generated data were presented. 
 During the workshop in Bilbao, a session was organized around interactions with other 
HUPO initiatives.  Drs. Rolf Apweiler and Henning Hermjakob from the European 
Bioinformatics Institute, reported on the HUPO Proteomics Standards Initiative (PSI).  The PSI 
was founded in 2002 to develop data representation formats in proteomics.  Released products so 
far are community standards for the representation of molecular interactions and mass spectra.  
The joint workshop of the PSI and the HUPO Publications Committee in San Francisco (April 
2006) attracted an attendance of approximately 100 bioinformaticians, experimentalists, and 
representatives from journals and standardization initiatives from related domains.  
Representatives of the PSI are currently collaborating with the HLPP to generate a representation 
of the HLPP data in PSI format.  They emphasized the need for comparing the data collected by 
the individual HUPO Initiatives, including HLPP, the brain proteome initiative (HBPP) and the 
plasma proteome initiative (HPPP).  Dr. Gil Omenn from the University of Michigan, chair of 
the HPPP, urged that comparisons of liver and plasma profiles across the two HUPO initiatives 
and in specimens from the same people or animals studied in the HLPP should be a standard 
feature.  The HPPP will share its protocols and would be pleased to participate in such cross-
analyses. 
 During this workshop in Bilbao, special guests were invited to discuss potential 
collaborations with HLPP.  Dr. Ron Appel from the Swiss Institute of Bioinformatics at the 
University of Geneva introduced activities on proteome imaging (Melanie / ImageMaster and 
MSight software for 2-D gel, respectively LC-MS data analysis) and protein identification and 
characterization (Aldente PMF identification) to identify mixtures of proteins, Popitam for 
MS/MS open-search identification, and GeneBio’s Phenyx comprehensive MS/MS identification 
platform.  He also showed the importance for correct validation of identification results.  Finally, 
swissPIT (Protein Identification Toolbox), the new pipeline designed for knowledge extraction 
from MS data developed within SwissBioGrid, was presented.  Dr. Juan-Pablo Albar from the 
Centro Nacional de Biotecnología, Bilbao introduced the ProteoRed initiative.  ProteoRed 
(Spanish National Network of Proteomics Facilities; www.proteored.org) aims to coordinate and 
integrate the activities of the proteomics facilities and services in Spain and to evaluate the 
quality of the services offered.  ProteoRed was formed in June 2005 and integrates 15 
laboratories and 5 associated laboratories.  Six working groups (WG) have been created to reach 
ProteoRed objectives: standardization of protocols and technologies, collection and handling of 
samples, bioinformatics support, functional organization of proteomics facilities and price 
policy, education, training and diffusion, and international networking.   
 Additional information on HLPP structure and activities can be obtained at the HUPO 
web page and in the newly launched HLPP Newsletters (http://www.hupo.org/research/hlpp/).  
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